Nustendi (Ezetimibe, Bempedoic Acid)

Nustendi is a combination lipid‑lowering therapy that targets cholesterol metabolism pathways.

• Primary hypercholesterolemia: helps achieve further LDL‑cholesterol reduction when statins alone are insufficient.
• Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol lowering in patients already on maximally tolerated statin therapy.
• Mixed dyslipidemia: contributes to lowering of total cholesterol and non‑HDL cholesterol in patients with combined lipid abnormalities.

• Ezetimibe blocks the intestinal Niemann‑Pick C1‑like 1 (NPC1L1) transporter, reducing dietary and biliary cholesterol absorption. Bempedoic acid is a pro‑drug activated in the liver that inhibits ATP‑citrate lyase, a key enzyme upstream of HMG‑CoA reductase in the cholesterol synthesis pathway. Together, they decrease the influx and synthesis of cholesterol, leading to lower circulating low‑density lipoprotein (LDL) concentrations.

Nustendi may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects

• Headache: mild to moderate intensity.
• Muscle pain (myalgia): occasional.
• Upper respiratory tract infection symptoms: such as sore sore.
• Diarrhea: mild and self‑limiting.
• Elevated liver enzymes: transient increase in laboratory tests.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown, rare but potentially life‑threatening.
• Acute hepatic    ");

Precautions

• Monitor liver function: baseline and periodic testing recommended.
• Assess cardiovascular risk: evaluate overall risk profile before initiating therapy.
• Review concomitant statin dose: adjust if high‑intensity statin therapy is used.
• Avoid in severe hepatic impairment: contraindicated in patients with significant liver disease.
• Pregnancy: consider  ");

Interactions

Major -